Extracellular vesicles (EVs) are essential components released by cells for intercellular communication, influencing various physiological and pathological processes. These membrane-bound sacs transfer proteins, nucleic acids, and lipids between cells, impacting cell behavior and function. EVs play a crucial role in homeostasis, tissue repair, immune responses, and disease progression, such as cancer and cardiovascular diseases. Beijing Evac Intell Biotechnology has developed a groundbreaking personalized tumor vaccine undergoing a trial for rare-cancer patients.
On the frontier of EV-based medicine, three Asia-Pacific companies are making significant strides in drug delivery. Shiftbio from South Korea, founded in 2020, is leading the charge by enhancing EV capabilities through surface modification techniques for cancer immunotherapy applications. Their innovative NNP-Design AI™ platform and large-scale manufacturing have produced a promising candidate, SBI-102, targeting liver cancer and promoting tissue regeneration. This article explores the cutting-edge advancements and potential impact of Asia-Pacific startups driving innovation in extracellular vesicle-based medicine.
Tags: biotechnology
Read more from genengnews.com